Search Videos and More
Video
Young-Onset Colorectal Cancer Center Annual Forum Research Keynote
At the Young-Onset Colorectal Cancer Center's third annual Patient and Family Forum, a Research Keynote lead by Jonathan Nowak, MD, PhD and Benjamin Schlechter, MD, discussed immunotherapy and CAR-T cell therapy in young-onset colorectal cancer.
News
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show
In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were presented by Dana-Farber's Ursula Matulonis, MD during a plenary session at the SGO 2022 Annual Meeting.
News
Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer. Results from this trial were shared by Panos Konstantinopolous, MD, PhD during a plenary session at the SGO 2022 Annual Meeting.
Video
2022 GU ASCO Prostate Cancer Highlights
Prostate Cancer Highlights featuring Jacob Berchuck, MD and Chris Sweeney, MBBS
Video
2022 GU ASCO Kidney Cancer Highlights
Kidney Cancer Highlights featuring Vincent Xu, MD and Toni Choueiri, MD
Video
2022 GU ASCO Bladder Cancer Highlights
Bladder Cancer Highlights featuring Guru Sonpavde, MD
Symposium
2022 ASCO GU Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review highlights from the 2022 ASCO GU Symposium.
News
Researchers Identify Promising Drug Target in Pediatric Neuroblastoma
Dana-Farber scientists have now teased apart the relationship between the proteins EP300 and CBP — to discover that EP300 is critical for a high-risk form of pediatric neuroblastoma.
Symposium
Hematologic Malignancies CME: 2021
The care of patients with hematologic malignancies is evolving rapidly. These video highlights discuss new developments in the diagnosis and treatment of hematologic malignancies presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).
News
Dana-Farber/Boston Children’s Exceeds Expected Outcomes for Stem Cell Transplants
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center was ranked as one of 15 transplant centers in the country that performed above the expected survival rate, according to a new report.
News
Dana-Farber Researchers Present Findings at 2022 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers presented important research studies during the 2022 ASCO Genitourinary (GU) Cancers Symposium, that took place from February 17-19, both virtually and in-person in San Francisco.
News
A Case of Mistaken Identity: Researchers Unmask Cellular Source of Barrett’s Esophagus
Two recent studies by Dana-Farber Cancer Institute scientists correct a longstanding misconception about the origins of Barrett’s esophagus, and in doing so may point to new avenues of treatment or prevention to lower the risk of esophageal cancer.